Findings of Research Misconduct, 76491-76492 [2012-31275]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 249 / Friday, December 28, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
tkelley on DSK3SPTVN1PROD with
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Shuang-Qing Zhang, Ph.D., Texas
Tech University Health Sciences Center:
Based on the report of an investigation
conducted by the Texas Tech University
Health Sciences Center (TTUHSC) and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Shuang-Qing Zhang, former
Postdoctoral Researcher, Department of
Pharmaceutical Sciences, TTUHSC,
engaged in research misconduct in
research supported by National Institute
of General Medical Sciences (NIGMS),
National Institutes of Health (NIH),
grant R01 GM069869.
ORI found that Respondent engaged
in research misconduct by the
falsification and fabrication of
plagiarized data that were included in
the publication: Zhang, S.Q. & Mehavr,
R. ‘‘Determination of dextramethylprednisolone conjugate with
glycine linker in rat plasma and liver by
high-performance liquid
chromatography and its application in
pharmacokinetics.’’ Biomed.
Chromatogr. 24(4):351–357, 2010
(hereafter the ‘‘BC 2010 article’’).
Specifically, ORI found that the
Respondent:
• Falsified Figures 2(c) and 3(c) of the
BC 2010 article by misrepresenting
HPLC data that he had plagiarized,
originally generated prior to the
Respondent’s arrival in the laboratory
by a former postdoctoral researcher; in
Figure 2(c), the Respondent claimed that
the HPLC chromatogram was of a
‘‘plasma sample obtained 12 h after
intravenous injection of DMP to rats at
a single dose of 5 mg/kg,’’ while the
actual chromatogram was of a
calibration test of 1 mg/ml of DMP added
to rat plasma, and similarly in Figure
3(c), the Respondent claimed that the
HPLC chromatogram was of a ‘‘liver
homogenate obtained 3 h after
intravenous dose of DMP at a dose of 5
mg/kg,’’ while the actual chromatogram
was of a calibration test of 2 mg/ml DMP
added to rat liver homogenate.
• Falsified and fabricated Figure 4 of
the BC 2010 article; in the top panel, the
Respondent reported the measurement
of DMP concentrations in plasma
VerDate Mar<15>2010
20:15 Dec 27, 2012
Jkt 229001
samples of three rats after a single
injection of 5 mg/kg DMP while the
actual data that he had plagiarized,
originally generated prior to the
Respondent’s arrival in the laboratory
by a former postdoctoral researcher, was
from a single rat. In the bottom panel,
the Respondent reported the
measurement of DMP concentrations in
liver samples obtained from three rats at
1, 30, 90, 180, 300, and 720 minutes
after a single injection of 5 mg/kg DMP,
requiring a total of 18 rats, while the
actual data that he had plagiarized,
originally generated prior to the
Respondent’s arrival in the laboratory
by a former postdoctoral researcher, was
from plasma samples from a single rat,
and the error bars for both panels were
fabricated.
Dr. Zhang has entered into a
Voluntary Settlement Agreement and
has voluntarily agreed:
(1) To have his research supervised
for a period of three (3) years;
Respondent voluntarily agrees that
within sixty (60) days of the effective
date of the Agreement, any institution
that submits an application for PHS
support for a research project on which
the Respondent’s participation is
proposed or that uses the Respondent in
any capacity on PHS supported
research, or that submits a report of
PHS-funded research in which the
Respondent is involved, must
concurrently submit a plan for
supervision of the Respondent’s
research to ORI for approval;
Respondent agrees that he will not
participate in any PHS-supported
research after sixty (60) days from the
effective date of the Agreement until an
appropriate supervision plan is
submitted to ORI; the supervision plan
must be designed to ensure the
scientific integrity of the Respondent’s
research contribution; and
(2) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of three (3)
years, beginning on December 4, 2012.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852,(240) 453–8800.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2012–31287 Filed 12–27–12; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
76491
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Martin Biosse-Duplan, D.D.S., Ph.D.,
Harvard School of Dental Medicine:
Based on the report of an investigation
conducted by the Harvard School of
Medicine (HSM) and Harvard School of
Dental Medicine (HSDM), the admission
of the Respondent, and additional
analysis conducted by ORI in its
oversight review, ORI found that Dr.
Martin Biosse-Duplan, former Research
Fellow, Department of Oral Medicine,
Infection, and Immunity, HSDM,
engaged in research misconduct in
research supported by National Institute
of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS), National
Institutes of Health (NIH), grant R01
AR054450.
ORI found that the Respondent
engaged in research misconduct
involving one (1) laboratory
presentation and two (2) published
abstracts:
• Boisse-Duplan, M., Stephens, S.,
Lai, F.P.L., Oelkers, M., Kitamura, D.,
Rottner, K., Horne, W., & Baron, R. ‘‘The
Association Between the Microtubule
Plus End Protein EB1 and Cortactin
Controls Podosomes and Bone
Resorption.’’ J Bone Min Res 26:Supl.1,
pS215.
• Boisse-Duplan, M., Stephens, S.,
Lai, F.P.L., Oelkers, M., Rottner, K.,
Horne, W., & Baron, R. ‘‘In Osteoclasts,
Dynamic Microtubules and their
Associated Protein EB1 Control
Podosomes and Bone Resorption
through Cortactin.’’ Bone 48:Suppl. 2,
pS97.
As a result of HSM’s and HSDM’s
investigation, the data were not
presented at the meetings and the
experiments reported in the abstracts
are being redone.
Specifically, ORI finds that
Respondent:
• Falsified Powerpoint slides and
spreadsheets for histomorphometric and
microCT results by using the values of
HS1 knockout (KO) mice and their
controls to represent the CathepsinK
cre-Cortactin KO mice and their
controls; Dr. Biosse-Duplan also
switched two sets of numbers between
the HS1 KO mice and their controls to
E:\FR\FM\28DEN1.SGM
28DEN1
tkelley on DSK3SPTVN1PROD with
76492
Federal Register / Vol. 77, No. 249 / Friday, December 28, 2012 / Notices
falsely demonstrate a difference in bone
density when there was none. The
numerical data were presented at a lab
meeting, and false text was included in
two submitted meeting abstracts
published in Bone 48:Suppl 2, pS97 and
J Bone and Mineral Research 25:Suppl
1, pS215.
Both the Respondent and HHS want
to conclude this matter without further
expenditure of time or other resources
and have entered into a Voluntary
Settlement Agreement (Agreement) to
resolve this matter.
Dr. Boisse-Duplan has entered into a
Voluntary Settlement Agreement and
has voluntarily agreed:
(1) That if within two (2) years from
the effective date of the Agreement
Respondent does receive or apply for
PHS support, Respondent agrees to have
his research supervised for a period of
two (2) years beginning on the date of
his employment in a research position
in which he receives or applies for PHS
support and to notify his employer(s)/
institution(s) of the terms of this
supervision; Respondent agrees that
prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research contribution;
Respondent agrees that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agrees to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) That if within two (2) years from
the effective date of the Agreement,
Respondent does receive or apply for
PHS support, Respondent agrees that
any institution employing him shall
submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
VerDate Mar<15>2010
20:15 Dec 27, 2012
Jkt 229001
as a consultant for a period of two (2)
years, beginning on December 4, 2012.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FOR FURTHER INFORMATION CONTACT:
Centers for Disease Control and
Prevention
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
[30Day-13–12NT]
David E. Wright,
Director, Office of Research Integrity.
Agency Forms Undergoing Paperwork
Reduction Act Review
[FR Doc. 2012–31275 Filed 12–27–12; 8:45 am]
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office Of The Secretary
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 10 3⁄8%, as fixed
by the Secretary of the Treasury, is
certified for the quarter ended
September 30, 2012. This interest rate is
effective until the Secretary of the
Treasury notifies the Department of
Health and Human Services of any
change.
Dated: December 17, 2012.
Margie Yanchuk,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2012–31284 Filed 12–27–12; 8:45 am]
BILLING CODE 4150–04–P
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Proposed Project
Early Hearing Detection and
Intervention– Pediatric Audiology Links
to Service (EHDI–PALS) Facility
Survey—New—National Center on Birth
Defects and Developmental Disabilities
(NCBDDD), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The Division of Human Development
and Disability, located within NCBDDD,
promotes the health of babies, children,
and adults, with a focus on preventing
birth defects and developmental
disabilities and optimizing the health
outcomes of those with disabilities.
Since the passage of the Early Hearing
Detection and Intervention (EHDI) Act,
97% of newborn infants are now
screened for hearing loss prior to
hospital discharge. However, many of
these infants have not received needed
hearing test and follow up services after
their hospital discharges. The 2009
national average loss to follow-up/loss
to documentation rate is at 45%. This
rate remains an area of critical concern
for state EHDI programs and CDC–EHDI
team’s goal of timely diagnosis by 3
months of age and intervention by 6
months of age. Many states cite the lack
of audiology resource as the main factor
behind the high loss to follow up. To
compound the problem, many pediatric
audiologists may be proficient
evaluating children age 5 and older but
are not proficient with diagnosing
infants or younger children because
children age 5 and younger requires a
different skill set. To date no existing
literature or database is available to help
states verify and quantify their states’
true follow up capacity.
E:\FR\FM\28DEN1.SGM
28DEN1
]]>Agencies
[Federal Register Volume 77, Number 249 (Friday, December 28, 2012)]
[Notices]
[Pages 76491-76492]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-31275]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Martin Biosse-Duplan, D.D.S., Ph.D., Harvard School of Dental
Medicine: Based on the report of an investigation conducted by the
Harvard School of Medicine (HSM) and Harvard School of Dental Medicine
(HSDM), the admission of the Respondent, and additional analysis
conducted by ORI in its oversight review, ORI found that Dr. Martin
Biosse-Duplan, former Research Fellow, Department of Oral Medicine,
Infection, and Immunity, HSDM, engaged in research misconduct in
research supported by National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS), National Institutes of
Health (NIH), grant R01 AR054450.
ORI found that the Respondent engaged in research misconduct
involving one (1) laboratory presentation and two (2) published
abstracts:
Boisse-Duplan, M., Stephens, S., Lai, F.P.L., Oelkers, M.,
Kitamura, D., Rottner, K., Horne, W., & Baron, R. ``The Association
Between the Microtubule Plus End Protein EB1 and Cortactin Controls
Podosomes and Bone Resorption.'' J Bone Min Res 26:Supl.1, pS215.
Boisse-Duplan, M., Stephens, S., Lai, F.P.L., Oelkers, M.,
Rottner, K., Horne, W., & Baron, R. ``In Osteoclasts, Dynamic
Microtubules and their Associated Protein EB1 Control Podosomes and
Bone Resorption through Cortactin.'' Bone 48:Suppl. 2, pS97.
As a result of HSM's and HSDM's investigation, the data were not
presented at the meetings and the experiments reported in the abstracts
are being redone.
Specifically, ORI finds that Respondent:
Falsified Powerpoint slides and spreadsheets for
histomorphometric and microCT results by using the values of HS1
knockout (KO) mice and their controls to represent the CathepsinK cre-
Cortactin KO mice and their controls; Dr. Biosse-Duplan also switched
two sets of numbers between the HS1 KO mice and their controls to
[[Page 76492]]
falsely demonstrate a difference in bone density when there was none.
The numerical data were presented at a lab meeting, and false text was
included in two submitted meeting abstracts published in Bone 48:Suppl
2, pS97 and J Bone and Mineral Research 25:Suppl 1, pS215.
Both the Respondent and HHS want to conclude this matter without
further expenditure of time or other resources and have entered into a
Voluntary Settlement Agreement (Agreement) to resolve this matter.
Dr. Boisse-Duplan has entered into a Voluntary Settlement Agreement
and has voluntarily agreed:
(1) That if within two (2) years from the effective date of the
Agreement Respondent does receive or apply for PHS support, Respondent
agrees to have his research supervised for a period of two (2) years
beginning on the date of his employment in a research position in which
he receives or applies for PHS support and to notify his employer(s)/
institution(s) of the terms of this supervision; Respondent agrees that
prior to the submission of an application for PHS support for a
research project on which the Respondent's participation is proposed
and prior to Respondent's participation in any capacity on PHS-
supported research, Respondent shall ensure that a plan for supervision
of Respondent's duties is submitted to ORI for approval; the
supervision plan must be designed to ensure the scientific integrity of
Respondent's research contribution; Respondent agrees that he shall not
participate in any PHS-supported research until such a supervision plan
is submitted to and approved by ORI; Respondent agrees to maintain
responsibility for compliance with the agreed upon supervision plan;
(2) That if within two (2) years from the effective date of the
Agreement, Respondent does receive or apply for PHS support, Respondent
agrees that any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(3) To exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of two (2) years, beginning on December 4,
2012.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2012-31275 Filed 12-27-12; 8:45 am]
BILLING CODE 4150-31-P
